MCID: 47X004
MIFTS: 44

47 Xxx Syndrome

Categories: Endocrine diseases, Fetal diseases, Nephrological diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for 47 Xxx Syndrome

MalaCards integrated aliases for 47 Xxx Syndrome:

Name: 47 Xxx Syndrome 19
Triple X Syndrome 19 42 58 75
Trisomy X 19 42 58 75
Trisomy X Syndrome 28 5 71
Triplo X Syndrome 19 42 75
47,xxx Syndrome 42 58 75
Xxx Syndrome 19 42 58
47,xxx 42 75
Triple-X Chromosome Syndrome 19
Triplo-X Syndrome 58
47, Xxx Syndrome 75
Triple-X Female 19

Characteristics:


Age Of Onset:

Trisomy X: Childhood,Infancy 58

Classifications:

Orphanet: 58  
Rare infertility disorders
Rare gynaecological and obstetric diseases
Rare endocrine diseases
Developmental anomalies during embryogenesis


External Ids:

MESH via Orphanet 44 D014314
ICD10 via Orphanet 32 Q97.0
UMLS via Orphanet 72 C0221033
Orphanet 58 ORPHA3375
UMLS 71 C0221033

Summaries for 47 Xxx Syndrome

MedlinePlus Genetics: 42 Trisomy X, also called triple X syndrome or 47,XXX, is characterized by the presence of an additional X chromosome in each of a female's cells. Although females with this condition may be taller than average, this chromosomal change typically causes no unusual physical features. Most females with trisomy X have normal sexual development and are able to conceive children.Trisomy X is associated with an increased risk of learning disabilities and delayed development of speech and language skills. Delayed development of motor skills (such as sitting and walking), weak muscle tone (hypotonia), and behavioral and emotional difficulties are also possible, but these characteristics vary widely. Seizures or kidney abnormalities occur in about 10 percent of affected females.

MalaCards based summary: 47 Xxx Syndrome, also known as triple x syndrome, is related to down syndrome and 48,xyyy. The drugs Aluminum hydroxide and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include kidney, prostate and breast, and related phenotypes are abnormality of chromosome segregation and hypotonia

GARD: 19 47 XXX syndrome, also called trisomy X or triple X syndrome, is characterized by the presence of an additional (third) X chromosome in each of a female's cells (which normally have two X chromosomes). An extra copy of the X chromosome is associated with tall stature, learning problems, and other features in some girls and women. Seizures or kidney abnormalities occur in about 10 percent of affected females. 47 XXX syndrome is usually caused by a random event during the formation of reproductive cells (eggs and sperm). An error in cell division called nondisjunction can result in reproductive cells with an abnormal number of chromosomes. Some females with 47 XXX syndrome have an extra X chromosome in only some of their cells; this is called 46,XX/47,XXX mosaicism.

Orphanet: 58 Trisomy X is a sex chromosome anomaly with a variable phenotype caused by the presence of an extra X chromosome in females (47,XXX instead of 46,XX).

Wikipedia: 75 Trisomy X, also known as triple X syndrome and characterized by the karyotype[note 1] 47,XXX, is a... more...

Related Diseases for 47 Xxx Syndrome

Diseases related to 47 Xxx Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 225)
# Related Disease Score Top Affiliating Genes
1 down syndrome 10.5
2 48,xyyy 10.4
3 cognitive function 1, social 10.2
4 amenorrhea 10.2
5 renal hypodysplasia/aplasia 1 10.2
6 premature menopause 10.2
7 ceroid lipofuscinosis, neuronal, 5 10.1
8 rett syndrome 10.1
9 46,xx sex reversal 1 10.1
10 patent ductus arteriosus 1 10.1
11 malaria, mild 10.1
12 renal hypodysplasia/aplasia 3 10.1
13 azoospermia 10.1
14 49, xxxxy syndrome 10.1
15 hypogonadotropic hypogonadism 10.1
16 gilles de la tourette syndrome 10.0
17 attention deficit-hyperactivity disorder 10.0
18 orofaciodigital syndrome viii 10.0
19 anxiety 10.0
20 tic disorder 10.0
21 turner syndrome 10.0
22 infertility 10.0
23 systemic lupus erythematosus 10.0
24 systemic lupus erythematosus 1 10.0
25 hypogonadism 10.0
26 lupus erythematosus 10.0
27 hypertelorism 10.0
28 thrombocytopenic purpura, autoimmune 10.0
29 telangiectasis 10.0
30 thrombocytopenia 10.0
31 heart septal defect 10.0
32 psychotic disorder 10.0
33 dysgerminoma 10.0
34 cleft lip 10.0
35 cleft lip/palate 10.0
36 cat eye syndrome 9.9
37 coarctation of aorta 9.9
38 cri-du-chat syndrome 9.9
39 glioma susceptibility 1 9.9
40 kabuki syndrome 1 9.9
41 marfan syndrome 9.9
42 otitis media 9.9
43 sarcoidosis 1 9.9
44 smith-magenis syndrome 9.9
45 adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency 9.9
46 camptodactyly-arthropathy-coxa vara-pericarditis syndrome 9.9
47 gaucher disease, type ii 9.9
48 hydrops fetalis, nonimmune 9.9
49 myelofibrosis 9.9
50 scott syndrome 9.9

Graphical network of the top 20 diseases related to 47 Xxx Syndrome:



Diseases related to 47 Xxx Syndrome

Symptoms & Phenotypes for 47 Xxx Syndrome

Human phenotypes related to 47 Xxx Syndrome:

58 30 (show all 21)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of chromosome segregation 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002916
2 hypotonia 58 30 Frequent (33%) Frequent (79-30%)
HP:0001252
3 global developmental delay 58 30 Frequent (33%) Frequent (79-30%)
HP:0001263
4 cognitive impairment 58 30 Frequent (33%) Frequent (79-30%)
HP:0100543
5 specific learning disability 58 30 Frequent (33%) Frequent (79-30%)
HP:0001328
6 epicanthus 58 30 Frequent (33%) Frequent (79-30%)
HP:0000286
7 clinodactyly of the 5th finger 58 30 Frequent (33%) Frequent (79-30%)
HP:0004209
8 tall stature 58 30 Frequent (33%) Frequent (79-30%)
HP:0000098
9 seizure 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001250
10 depression 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000716
11 tremor 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001337
12 hypertelorism 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000316
13 hip dysplasia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001385
14 attention deficit hyperactivity disorder 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0007018
15 anxiety 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000739
16 secondary amenorrhea 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000869
17 pectus excavatum 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000767
18 renal hypoplasia/aplasia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0008678
19 upslanted palpebral fissure 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000582
20 joint hyperflexibility 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0005692
21 multicystic kidney dysplasia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000003

Drugs & Therapeutics for 47 Xxx Syndrome

Drugs for 47 Xxx Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
2 Vaccines Phase 4
3
Azelaic acid Approved Phase 3 123-99-9 2266
4
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
5
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
6 Dermatologic Agents Phase 3
7 Neurotransmitter Agents Phase 3
8
Brimonidine Tartrate Phase 3 70359-46-5
9 Adrenergic alpha-Agonists Phase 3
10 Adrenergic Agonists Phase 3
11 Adrenergic Agents Phase 3
12 Antihypertensive Agents Phase 3
13
Eptifibatide Approved, Investigational Phase 2 188627-80-7 448812
14 Platelet Aggregation Inhibitors Phase 2
15 Hormones Phase 2
16 Emollients Phase 1
17 Immunoglobulins Phase 1
18 Antibodies, Monoclonal Phase 1
19 Antibodies Phase 1
20 Immunologic Factors Phase 1
21
Acetaminophen Approved 103-90-2 1983
22
Ibuprofen Approved 15687-27-1 3672
23
Testosterone Approved, Investigational 58-22-0 5408 6013
24 Analgesics
25 Antirheumatic Agents
26 Antipyretics
27 Cyclooxygenase Inhibitors
28 Anti-Inflammatory Agents, Non-Steroidal
29 Anti-Inflammatory Agents
30 Analgesics, Non-Narcotic

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 A Phase IV Open, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of a Pediatric Presentation (0.25 ml) of the Virosomal Hepatitis A Virus (HAV) Vaccine HAVpur in Healthy Young Children Aged Between and Including 18 Months to 47 Months, Using a 0/6 Month Immunization Schedule Completed NCT01349829 Phase 4
2 A Phase 3, Randomized, Observer-Blind, Multicenter, Noninferiority Study to Evaluate Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) and a United States Licensed Quadrivalent Influenza Virus Vaccine (QIV) in Healthy Subjects 6 Months Through 47 Months Completed NCT04074928 Phase 3
3 A Multicenter, Randomized, Controlled, Double-masked, Crossover Design Study to Compare Efficacy and Assess Safety of CD07805/47 Gel 0.5% Applied Once Daily vs Azelaic Acid Gel 15% Applied Twice Daily in Subjects With Erythema of Rosacea Completed NCT01659853 Phase 3 CD07805/47 gel 0.5%/CD07805/47 Vehicle;azelaic acid gel 15%
4 A Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of CD07805/47 Gel 0.5% Applied Topically Once Daily for up to 52 Weeks in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT01318733 Phase 3 CD07805/47 gel 0.5%
5 Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea Completed NCT01789775 Phase 3 Drug: CD07805/47 gel;CD07805/47 gel Placebo
6 A Multicenter, Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Safety of CD07805/47 Gel Applied Topically Once Daily in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT01355471 Phase 3 CD07805/47 Gel;Placebo
7 A Multicenter, Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Safety of CD07805/47 Gel Applied Topically Once Daily in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT01355458 Phase 3 CD07805/47 gel;Placebo
8 A Phase 3, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus' Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to a Non-Influenza Vaccine When Administrated in Healthy Subjects Aged 6 Months Through 47 Months Recruiting NCT03932682 Phase 3
9 Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema Withdrawn NCT01882712 Phase 3 CD07805/47 Gel 0.5%;CD07805/47 Gel Placebo
10 A 4-week, Randomized, Double-blind, Parallel-group, Vehicle-controlled, Multicenter Study Investigating the Efficacy and Safety of CD07805/47 Gel 0.5% Applied Topically Once Daily (QD), and CD07805/47 Gel 0.18% Applied Topically Once Daily (QD) or Twice Daily (BID), in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT01174030 Phase 2 CD07805/47 Gel;Vehicle Gel
11 Effect of CD07805/47 Gel in Subjects Presenting With Flushing Related to Erythematotelangiectatic or Papulopustular Rosacea Completed NCT02300129 Phase 2 CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo;Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo;CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47;Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47
12 Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Dose-Finding Study Investigating the Pharmacodynamics and Safety of Three Concentrations of CD07805/47 Topical Gel (0.07%, 0.18%, and 0.50%), Applied in Subjects With Moderate to Severe Erythematotelangiectatic Rosacea Completed NCT00989014 Phase 2 CD07805/47;CD07805/47 placebo
13 A Dbl-blind,Randomized,Controlled,Phase IIb Field Trial in 12-47 Month-old Children in Western Kenya to Eval the Efficacy,Safety and Immunogenicity of the FMP1/AS02A Malaria Vaccine vs Rabies Vaccine Completed NCT00223990 Phase 2
14 IntraCoronary Treatment With Integrilin To Improve ANgiographic Outcomes (IC TITAN - TIMI 47) Trial Terminated NCT00719914 Phase 2 eptifibatide;normal saline
15 A Phase II Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer (47-02-001) Terminated NCT00585416 Phase 2 CGC-11047
16 A 47 Hour, Single Application, Occlusive Forearm Skin Patch Test to Assess, Under Dermatological Control, the Acute Cutaneous Tolerance of Project Storm on the Forearm of Adult Subjects With Dry/Atopic and Very Dry/Atopic Skin Completed NCT02620293 Phase 1
17 A Phase 1a Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas Completed NCT03763149 Phase 1
18 A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignancies Completed NCT03717103 Phase 1 IBI188
19 Double-blind,Randomized,Controlled,Dose Escalation Phase 1 Trial in 12-47 Month Old Children in Western Kenya to Evaluate the Safety and Immunogenicity of WRAIR's MSP-1(FMP1) Malaria Vaccine Adjuvanted in GSK's AS02A Versus Rabies Vaccine. Completed NCT00317473 Phase 1
20 Non-Invasive Determination of Fetal Chromosome Abnormalities Unknown status NCT00891852
21 X-chromosome Inactivation, Epigenetics and the Transcriptome Completed NCT01678261
22 Cardiometabolic Profiles of Pubertal Boys With Klinefelter Syndrome With or Without One Year of Exogenous Testosterone Treatment Completed NCT02723305
23 Fertility Preservation in Cases of Spermatogenesis Failure : Prospective Study for Klinefelter Syndrome With Non-mosaic Karyotype (47, XXY, Homogeneous) Completed NCT01918280
24 Clinical Immunization Safety Assessment (CISA): A Study to Assess the Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine (IIV) Administered to Children 6 Through 47 Months of Age Completed NCT02212990
25 The eXtroardinarY Babies Study: Natural History of Health and Neurodevelopment in Infants and Young Children With Sex Chromosome Trisomy Recruiting NCT03396562
26 Randomized Controlled Trial for the Effect of ODISEA 2.0 Video-feedback Intervention in Promoting Parenting Skills in Caregivers of Children Between 10 and 47 Months Not yet recruiting NCT04244318

Search NIH Clinical Center for 47 Xxx Syndrome

Genetic Tests for 47 Xxx Syndrome

Genetic tests related to 47 Xxx Syndrome:

# Genetic test Affiliating Genes
1 Trisomy X Syndrome 28

Anatomical Context for 47 Xxx Syndrome

Organs/tissues related to 47 Xxx Syndrome:

MalaCards : Kidney, Prostate, Breast, Lymph Node, Bone Marrow, Lung, Liver

Publications for 47 Xxx Syndrome

Articles related to 47 Xxx Syndrome:

(show top 50) (show all 30138)
# Title Authors PMID Year
1
Corrigendum to "Magnesium cationic cue enriched interfacial tissue microenvironment nurtures the osseointegration of gamma-irradiated allograft bone" [Bioact. Mater. 10C (April 2022) 32-47]. 62
35663337 2023
2
The adsorption and absorption kinetics of BDE-47 by Chlorella sp. and the role of extracellular polymer substances influenced by environmental factors. 62
36328222 2023
3
Corrigendum to 'Cavitation emissions nucleated by Definity infused through an EkoSonic catheter in a flow phantom' [Ultrasound in Med & Biol. 47 (2021) 693-709]. 62
36266144 2023
4
Biotransformation kinetics and pathways of 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) and its hydroxylated and methoxylated derivatives (6-OH-BDE-47 and 6-MeO-BDE-47) in earthworms (Eisenia fetida). 62
36152865 2023
5
Effects of the synthetic progestin levonorgestrel on some aspects of thyroid physiology in common carp (Cyprinus carpio). 62
36244424 2023
6
Occurrence and ecological risk assessment of 2,2',4,4'-tetrabromodiphenyl ether and decabromodiphenyl ether in surface waters across China. 62
36375608 2023
7
Manure- and straw-derived biochars reduce the ecological risk of PBDE and promote nitrogen cycling by shaping microbiomes in PBDE-contaminated soil. 62
36400195 2023
8
Polybrominated diphenyl ethers interact with the key protein involved in carbohydrate metabolism in rice. 62
36265726 2023
9
Neuro- and hepato-toxicity of polystyrene nanoplastics and polybrominated diphenyl ethers on early life stages of zebrafish. 62
36272476 2023
10
Adipose tissue levels of polybrominated diphenyl ethers in relation to prognostic biomarkers and progression-free survival time of breast cancer patients in eastern area of southern China: A hospital-based study. 62
36370816 2023
11
Exposure to flame retardants in European children - Results from the HBM4EU aligned studies. 62
36442457 2023
12
First molecular detection of Mycoplasma ovis in horses from Brazil. 62
36162457 2023
13
Characteristics of thermal pollution from stormwater runoff from impermeable/permeable pavement surfaces via a lab-scale experiment. 62
36283172 2023
14
Protein profiling and classification of commercial quinoa grains by MALDI-TOF-MS and chemometrics. 62
35986991 2023
15
Seasonal variation in antibiotic resistance genes and bacterial phenotypes in swine wastewater during three-chamber anaerobic pond treatment. 62
36208778 2023
16
Profiles and determinants of dicofol, endosulfans, mirex, and toxaphenes in breast milk samples from 10 prefectures in Japan. 62
36419270 2023
17
Potential effect of heat adaptation on association between number of heatstroke patients transported by ambulance and wet bulb globe temperature in Japan. 62
36328225 2023
18
Workplace gender harassment, illegitimate tasks, and poor mental health: Hypothesized associations in a Swedish cohort. 62
36413856 2022
19
The effect of Moringa oleifera capsule in increasing breast milk volume in early postpartum patients: A double-blind, randomized controlled trial. 62
36440058 2022
20
Outcomes in patients with ischaemic stroke undergoing endovascular thrombectomy: Impact of atrial fibrillation. 62
36473398 2022
21
[Genetic analysis of a case with a supernumerary marker derived from chromosome 9]. 62
36453970 2022
22
Incidence and Trends in the Use of Palliative Care among Patients with Reduced, Middle-Range, and Preserved Ejection Fraction Heart Failure. 62
35763838 2022
23
Quantification of genetic variability and stable genotype selection over the years in the germplasm of critically endangered Prishanparni (Uraria picta Desv.). 62
34994919 2022
24
Characteristics and methodological standards across systematic reviews with Meta-analysis of efficacy and/or effectiveness of influenza vaccines: an overview of reviews. 62
36000220 2022
25
Prolonged cycling reduces power output at the moderate-to-heavy intensity transition. 62
36127418 2022
26
Operative trauma volume is not related to risk-adjusted mortality rates among Pennsylvania trauma centers. 62
36049153 2022
27
Bariatric surgery practice patterns among pediatric surgeons in the United States. 62
35927071 2022
28
Deep learning-based acceleration of Compressed Sense MR imaging of the ankle. 62
35751695 2022
29
Genome-wide identification and expression analysis of Raf-like kinase gene family in pepper (Capsicum annuum L.). 62
35435138 2022
30
Higher-order trajectories of pain and depressive symptoms link midlife financial stress to women's well-being in later life. 62
34693847 2022
31
Spontaneous labor patterns among women attempting vaginal birth after cesarean delivery. 62
35098866 2022
32
How Is Health Equity Assessed in Cochrane Musculoskeletal Reviews? 62
35970529 2022
33
Projecting the Economic Impact of Compensating Living Kidney Donors in the United States: Cost-Benefit Analysis Demonstrates Substantial Patient and Societal Gains. 62
35690519 2022
34
Clinical outcomes of grafted vs. percutaneous axillary intra-aortic balloon pump support as a bridge to transplantation: a propensity score-matched analysis. 62
35794489 2022
35
Real-life clinical impact of a five-tiered classification of pituitary tumors. 62
36315463 2022
36
Supporting Healthy Weight in Statewide Quality Rating and Improvement Systems: A Review of 2020 Standards and Comparison to 2015 Standards. 62
36472466 2022
37
High genotypic diversity of human papillomavirus among women in Cameroon: implications for vaccine effectiveness. 62
36313603 2022
38
A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases. 62
36030187 2022
39
Birth weight and intra-amniotic inflammatory and infection-related complications in pregnancies with preterm prelabor rupture of membranes: a retrospective cohort study. 62
34320890 2022
40
The role of acupuncture and moxibustion in the treatment, prevention, and rehabilitation of patients with COVID-19: A scoping review. 62
35967901 2022
41
Polymer aging affects the bioavailability of microplastics-associated contaminants in sea urchin embryos. 62
36206916 2022
42
Flow diverter devices in the treatment of complex middle cerebral artery aneurysms when surgical and endovascular treatments are challenging. 62
36201991 2022
43
AFSOS-SFRO-SFH-SFNEP-SFCE-GFRP guidelines on radio-induced nausea and vomiting. 62
36223807 2022
44
Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial. 62
36188435 2022
45
Design, synthesis and biological evaluation of new quinazolinone-benzopyran-indole hybrid compounds promoting osteogenesis through BMP2 upregulation. 62
36219902 2022
46
C/D box snoRNA SNORD113-6 guides 2'-O-methylation and protects against site-specific fragmentation of tRNALeu(TAA) in vascular remodeling. 62
36250206 2022
47
Nutritional status is associated with prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. 62
36455517 2022
48
PBDEs disrupt homeostasis maintenance and regeneration of planarians due to DNA damage, proliferation and apoptosis anomaly. 62
36371889 2022
49
Behavioral changes and transcriptomic effects at embryonic and post-embryonic stages reveal the toxic effects of 2,2',4,4'-tetrabromodiphenyl ether on neurodevelopment in zebrafish (Danio rerio). 62
36423367 2022
50
Milligan-Morgan hemorrhoidectomy vs. hemorrhoid artery ligation and recto-anal repair: a comparative study. 62
36474223 2022

Variations for 47 Xxx Syndrome

ClinVar genetic disease variations for 47 Xxx Syndrome:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 overlap with 824 genes GRCh37/hg19 Xp22.33-q28(chrX:1-155270560) CN GAIN Pathogenic
1703579 GRCh37: X:1-155270560
GRCh38:

Expression for 47 Xxx Syndrome

Search GEO for disease gene expression data for 47 Xxx Syndrome.

Pathways for 47 Xxx Syndrome

GO Terms for 47 Xxx Syndrome

Sources for 47 Xxx Syndrome

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....